By Brian Buntz | November 18, 2026Recursion’s Phase 3 FAP trial will count large-polyp removals as events under FDA-agreed design Recursion’s Phase 3 trial of REC-4881 in familial adenomatous polyposis will count removal of adenomas 10 mm or larger as events under an FDA-agreed design.